Literature DB >> 308513

Correlation of adenosine deaminase activity with cell surface markers in acute lymphoblastic leukemia.

J F Smyth, D G Poplack, B J Holiman, B G Leventhal, G Yarbro.   

Abstract

Adenosine deaminase (ADA) activity has been measured in the lymphoblasts of 23 untreated patients with acute lymphoblastic leukemia and related to the presence or absence of immunologic cell surface markers. The mean ADA activity in the acute lymphoblastic leukemia population as a whole was increased fourfold over that in normal lymphocytes. 9 of the 23 patients were classified as thymus-derived (T-) cell acute lymphoblastic leukemia on the basis of erythrocyte rosette positivity; the remaining 14 patients had null-cell leukemia. The mean ADA activity (ADA U/mg protein) of T-cell lymphoblasts (102 U) was 3 times higher than the mean of null lymphoblasts (30 U). This difference is statistically significant (P less than 0.02). Measurement of ADA activity offers a biochemical method of distinguishing between immunological subtypes of lymphoblasts which may be of prognostic and therapeutic value.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 308513      PMCID: PMC371818          DOI: 10.1172/JCI109179

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  19 in total

1.  Adenosine deaminase activity in lymphoid cells during antibody production.

Authors:  J G HALL
Journal:  Aust J Exp Biol Med Sci       Date:  1963-02

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

Review 3.  Acute leukemia: the use of surface markers in classification.

Authors:  G B Humphrey; J Lankford
Journal:  Semin Oncol       Date:  1976-09       Impact factor: 4.929

4.  Enhanced binding of neuraminidase-treated sheep erythrocytes to human T lymphocytes.

Authors:  M S Weiner; C Bianco; V Nussenzweig
Journal:  Blood       Date:  1973-12       Impact factor: 22.113

5.  Adenosine-deaminase deficiency and combined immunodeficiency syndrome.

Authors:  J Dissing; B Knudsen
Journal:  Lancet       Date:  1972-12-16       Impact factor: 79.321

6.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

7.  Identification of the enzymatic pathways of nucleotide metabolism in human lymphocytes and leukemia cells.

Authors:  E M Scholar; P Calabresi
Journal:  Cancer Res       Date:  1973-01       Impact factor: 12.701

8.  In vivo toxicity to lymphoid tissue by 2'-deoxycoformycin.

Authors:  J F Smyth; R C Young; D M Young
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

9.  Surface markers and prognostic factors in acute lymphoblastic leukemia.

Authors:  I Tsukimoto; K Y Wong; B C Lampkin
Journal:  N Engl J Med       Date:  1976-01-29       Impact factor: 91.245

10.  Adenosine deaminase activity in peripheral blood cells of patients with haematological malignancies.

Authors:  J Meier; M S Coleman; J J Hutton
Journal:  Br J Cancer       Date:  1976-03       Impact factor: 7.640

View more
  11 in total

1.  Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin.

Authors:  M S Hershfield; J Kurtzberg; E Harden; J O Moore; J Whang-Peng; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

2.  Adenosine deaminase and nucleoside phosphorylase activities in normal human blood mononuclear cell subpopulations.

Authors:  R P MacDermott; G L Tritsch; J F Formeister
Journal:  Clin Exp Immunol       Date:  1980-11       Impact factor: 4.330

3.  Immunologic diagnosis and monitoring of human acute leukemias: a review.

Authors:  M Maheu; M A Baker; J A Falk; R N Taub
Journal:  Am J Pathol       Date:  1981-04       Impact factor: 4.307

Review 4.  Biochemical enzyme analysis in acute leukaemia.

Authors:  H G Drexler; G Gaedicke; J Minowada
Journal:  J Clin Pathol       Date:  1985-02       Impact factor: 3.411

Review 5.  Enzymes of purine metabolism in lymphoid neoplasms, clinical relevance for treatment with enzyme inhibitors.

Authors:  A D Ho; K Ganeshaguru
Journal:  Klin Wochenschr       Date:  1988-06-01

6.  Localization and identity of adenosine deaminase-positive cells in tissues of the young rat and calf.

Authors:  B E Chechik; R Baumal; S Sengupta
Journal:  Histochem J       Date:  1983-04

7.  Purine metabolism in myeloid precursor cells during maturation. Studies with the HL-60 cell line.

Authors:  D L Lucas; H K Webster; D G Wright
Journal:  J Clin Invest       Date:  1983-12       Impact factor: 14.808

8.  Ecto-enzyme activity of human erythrocyte adenosine deaminase.

Authors:  K Bielat; G L Tritsch
Journal:  Mol Cell Biochem       Date:  1989-04-11       Impact factor: 3.396

Review 9.  Enzyme and membrane markers in leukaemia: recent developments.

Authors:  A V Hoffbrand; G Janossy
Journal:  J Clin Pathol       Date:  1981-03       Impact factor: 3.411

10.  High-resolution metabolomics of occupational exposure to trichloroethylene.

Authors:  Douglas I Walker; Karan Uppal; Luoping Zhang; Roel Vermeulen; Martyn Smith; Wei Hu; Mark P Purdue; Xiaojiang Tang; Boris Reiss; Sungkyoon Kim; Laiyu Li; Hanlin Huang; Kurt D Pennell; Dean P Jones; Nathaniel Rothman; Qing Lan
Journal:  Int J Epidemiol       Date:  2016-10-05       Impact factor: 7.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.